loader2
Login Open ICICI 3-in-1 Account
  • Text Size
  • Text to Speech
  • Color Contrast
  • Pause Animations

Open ICICI
3-in-1 Account

Manage your Savings, Demat and Trading Account conveniently at one place

+91

BLOG

Pfizer revenues grew 8 percent to Rs 653 crore

ICICIdirect Research 29 Jul 2026 DISCLAIMER

News: Pfizer revenues grew ~8% to ~Rs 653.2 crore, driven by growth in power brands such as Eliquis (CVS), and Magnex (Anti-infective), Meronem (anti-infective), Zavicefta(Anti-infective) among others. The newly launched Prevnar 20 vaccine also contributed to the growth. There was a de-growth in other power brands such as Becosules (VMS), Mucaine (Antacid), Minipress XL (CVS). EBITDA grew ~18% with a margin increased by 308 bps YoY to 37.9% due despite GPM de-growth by 173 bps to 63.2%. PAT grew 6.6% with a margin contraction by ~49 bps (due to lower other income) to ₹204.5 crore

View: As per IQVIA, the growth stood at ~11%. Structural reforms like revised go-to-market model for some products to enhance market penetration focusing on three core divisions of Internal medicine, Vaccines and Hospitals would be the main driver for growth from hereon. A case in point is the launch of pneumococcal conjugate vaccine Prevnar 20 which is an improved version of Prevnar 13. We continue to monitor progress on an overall basis rather than quarterly gyrations.

Impact: Positive

Download ICICI Direct app

Invest, Track, and Manage your Portfolio Anytime, Anywhere

Download ICICI Direct app

Invest, Track, and Manage your Portfolio Anytime, Anywhere